… Analyst & Investor Axiomer® technology R&D Event This virtual event on March 29, … by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the …
… Axiomer Technology - Therapeutic oligonucleotides for … site-specific A-to-I editing by endogenous ADAR enzymes Axiomer® platform applicability and potential in …
This is Gerard Platenburg's presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.
… chemical modifications to improve ADAR potency and unlock Axiomer broad applicability RNA Editing Summit (2023) Lenka … and oligonucleotide design. The potential of the Axiomer platform in multiple organs, as well as its …
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration … directed to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million …
… ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio LEIDEN, Netherlands & CAMBRIDGE, Mass., … a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in June 2021 with the …
… ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration Partnership focused on … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Axiomer has the potential to restore precise levels of the …
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 LEIDEN, … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today announced a …
… ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 Platform … transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted …
